Primary source: There is more detail in the declaration
APHA is now conducting bluetongue sample testing at its Weybridge laboratories alongside The Pirbright Institute to expedite test results amid an outbreak, and necessitates that submission forms be securely attached on the outside of sample parcels.
This regulatory update is crucial as it can significantly impact the management of animal disease safety and response efforts, ensuring timely testing and reporting, which is vital for controlling the outbreak and protecting animal health.
Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.
The Animal and Plant Health Agency (APHA) has initiated testing of bluetongue samples at its Weybridge facility in collaboration with The Pirbright Institute. This is part of a national response to an unprecedented scale of the bluetongue disease outbreak in the UK. Changes include updated submission procedures for samples and enhancements in reporting test results.
What changed: APHA is now conducting bluetongue sample testing at its Weybridge laboratories alongside The Pirbright Institute to expedite test results amid an outbreak, and necessitates that submission forms be securely attached on the outside of sample parcels.
Why it matters: This regulatory update is crucial as it can significantly impact the management of animal disease safety and response efforts, ensuring timely testing and reporting, which is vital for controlling the outbreak and protecting animal health.
Practical implication: Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
